Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Jones, Travis M; Johnson, Steven W; DiMondi, V Paul; Wilson, Dustin T

Jones, Travis M; Johnson, Steven W; DiMondi, V Paul; Wilson, Dustin T.

Afiliación

Jones TM; Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Campbell University, Buies Creek, USA; Department of Pharmacy, Duke University Hospital, Durham, USA.
Johnson SW; Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Campbell University, Buies Creek, USA; Department of Pharmacy, Forsyth Medical Center, Novant Health, Winston-Salem, USA.
DiMondi VP; Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Campbell University, Buies Creek, USA; Department of Pharmacy, Durham VA Medical Center, Durham, NC, USA.
Wilson DT; Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Campbell University, Buies Creek, USA; Department of Pharmacy, Duke University Hospital, Durham, USA.

Infect Drug Resist ; 9: 119-28, 2016.

Article en En | MEDLINE | ID: mdl-27354817

Palabras clave

ABSSSI; CABP; JNJ-Q2; MRSA; fluoroquinolone

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Infect Drug Resist Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google